$OVID

Ovid Therapeutics Inc. (OVID): Submission of Matters to a Vote of Security Holders

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ovid-20260611 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 11, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$OVID
Neutral
high confidence
Mentioned
$OVID
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OVIDNeutralLow
01

Why it matters

The disclosure confirms quorum and final results for three proxy proposals: director election (Jeremy M. Levin), advisory say-on-pay, and ratification of KPMG as independent auditor for FY ending Dec. 31, 2026.

02

Market read

Primarily confirms governance outcomes; not a catalyst for earnings, trials, or financing based on the text provided.

03

What to watch

Traders should verify whether the director election involved any contested outcome or whether there were unusual vote patterns; this 8-K alone does not indicate such issues.

Relevance 6/10Novelty 2/10Timing: Filed June 11, 2026 (after June 10 annual meeting)

Background

Item 5.07 of Form 8-K summarizes matters submitted to a vote of security holders following the annual meeting.

Company-level read

Ticker impact

$OVIDNeutralHigh confidence
Context

Ovid Therapeutics filed an 8-K reporting final voting results from its June 10, 2026 annual meeting (director election, say-on-pay, auditor ratification).

Expected impact

Limited near-term impact; any reaction is likely muted unless investors were focused on governance outcomes.

Evidence & confidence

The filing is a standard Item 5.07 disclosure of proxy vote tallies (director election, advisory compensation approval, KPMG ratification) without additional guidance or material events.

Market effects

No direct read-across to biotech sector fundamentals; governance vote outcomes are company-specific and typically non-informational.

None.

None.

Counterpoint

If the market had been uncertain about board composition or auditor continuity, the vote could reduce overhang, but the filing provides no indication of controversy or change in direction.

Key entities

  • Ovid Therapeutics Inc.

    Nasdaq-listed company filing Item 5.07 8-K with annual meeting voting results.

  • Jeremy M. Levin

    Elected director for a three-year term based on the reported vote totals.

  • KPMG LLP

    Ratified as independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

$OVIDMedAI 8/10

Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia

Experts discussed advancements in precision psychiatry for schizophrenia, including computational phenotyping and new drugs. Brannan highlighted xanomeline-trospium (Cobenfy), approved in 2024, showing significant symptom reduction. Gopal noted patient improvements, while Zhong presented preclinical data on OV4071. Key companies involved: Karuna Therapeutics (Cobenfy), Ovid Therapeutics (OV4071).

$OVIDMed

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two

Ovid Therapeutics (OVID) reported Q2 results with $169.8M cash, funding operations into 2029. Progress on OV4071 and OV329 clinical trials. R&D expenses rose to $10M, net loss widened to $15M. Soticlestat deal brings potential $294.5M in milestones and royalties. Share count increased after warrant exercises.